Sarepta makes sharp move to the upside as the Street gets bullish

|About: Sarepta Therapeutics, Inc. (SRPT)|By:, SA News Editor

At the risk of inducing eteplirsen/ drisapersen news-fatigue, it's worth noting that shares of Sarepta Therapeutics (SRPT +17.2%) have reversed course dramatically over the course of the day.

Investors and the sell-side alike have apparently digested Friday's drisapersen (RNA -67.1%) news and determined that the chances of a favorable regulatory outcome for eteplirsen are still good.

Also, Piper Jaffray joins Stifel and Deutsche (see previous) in the bull camp, upgrading SRPT to Overweight (price target is $58).

More here